Complement testing—past, present, and future

By Laura Oversmith, BSB F

or more than 60 years, clinicians have been assessing complement components to measure deficiencies or abnormalities. It is very important to understand the causes of low or absent complement so that appropriate treatment and care may be given. Complement analysis is also used to define disease severity and response to therapy, making it very useful for patient management.

History of complement

How did “complement” get its name? In the late 19th century, the focus of scientific research was on the human body’s defense against microbial infection. Scientists tried to ascertain what part of the blood destroyed invad- ing bacteria. The Theory of Metchnikoff proposed that phagocytes ingested and destroyed invading bacteria and therefore provided the basis of innate cellular immu- nity. Further, Paul Ehrlich provided the theoretical basis for immunology; he surmised that between the antigen and the antibody there was an additional immune mol- ecule called a “complement.”1

Paul Ehrlich and Ilya Ilich

Metchnikoff were both awarded the Nobel Prize for Medicine in 1908.

What is the Complement System?

The Complement System is composed of 30 blood proteins that are numbered as complement proteins: C1 to C9 with some appended with additional letter desig- nation, e.g. C3c, C5a, C5b. These proteins function in an ordered fashion to defend against infection, coat microbes, send chemical signals, and create the membrane attack complex (MAC), which results in lysis of the pathogen. Most complement proteins are produced in the

liver. There are three key biochemical pathways that activate the complement system: Classical Pathway, Alternative Pathway, and Lectin Pathway. All of these pathways have distinct recognition molecules or activation triggers.

Three reasons to measure complement There are a several reasons why complement component measurements are requested to assess deficiencies or abnormalities in the complement system. First, clinicians may be looking to see whether a

patient has an absence of a specific protein, or a pro- tein that is non-functional. This is generally a primary immunodeficiency. Second, the clinician could be looking for consumption, where an over-activation of complement pathways results in low levels of comple- ment proteins. Third, a relatively new area for comple- ment measurement is monitoring patients who are on immunosuppressive drugs.

Clinical presentations vary

The clinical presentations of patients with complement abnormalities usually fall into one of the following categories:


t Multi-system rheumatic diseases, such as systemic lupus erythematosus, juvenile rheumatoid arthritis, and Crohn’s

disease t Kidney disease t Hemolytic anemia t Recurrent or overwhelming infections

“The value of 50”

CH50 testing is the most common assay used to screen patients for the functional activity of the classical complement pathway, and in the work up of comple- ment deficiency. Guidelines from The National Immune Deficiency Foundation and the European Society for Immunodeficiencies recommend screening with the CH50 assay in the diagnostic workup of complement deficiency.2

CH50 uses the Classical Pathway and its components of the pathway: C1 through C9. Each of these components is required to be activated in order obtain a normal value indicating that the immune system is effectively eliminat- ing pathogens, damaged cells, etc. The starting point of the pathways is at the C1 complex which recognizes anti- body molecules and initiates a cascade. Next is a confor- mational change allowing activation and cleavage of the next protein in the complement pathway. This is followed by a series of cleavage events—where one protein activates another, which activates another, then another—like a row of falling dominoes—until a protein called C5 convertase is generated. This C5 convertase cleaves complement pro- tein 5 or C5 into C5a and C5b, initiating the formation of the MAC. The MAC is a C5b-9 complex, which can cause pores or holes to form on the surface of the pathogen or cell that the body needs to eliminate, ultimately causing its destruction. It is the formation of these membrane attack complexes that are detected and measured when 50 percent of them are lysed, thus the name “CH50.”

How to test for CH50 Presently, there are three methodologies for testing CH50: 1. Hemolytic: an old, complex, and laborious method first described by the esteemed Manfred Mayer in 1958. It uses sheep erythrocytes sensitized with anti-sheep antibodies. Complement activation leads to MAC for- mation and 50 percent hemolysis of the erythrocytes. Increased complement activation gives increased hemo- lysis, and the amount of hemoglobin release results in a red color. The more hemolysis, the darker the red color. 2. ELISA: uses a microtiter plate that combines prin- ciples of the hemolytic method; hemolysis is measured spectrophotometrically. The assay takes more than 2.5 hours to complete. 3. Liposome: a relatively new method that is an automated assay. The process entails antigen labeled liposomes sensi- tized by antibodies. The complements are activated by the antigen antibody complex that will break the liposome

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48